GP IIb/IIIa-Mediated Platelet Activation and Its Modulation of the Immune Response of Monocytes Against Candida albicans

Zheng, Lin; Duan, Zhimin; Tang, Dingjie; He, Yanzhi; Xu, Chen; Chen, Qing; Li, Min; Li, Min

doi:10.3389/fcimb.2021.783085

Cited by 3 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[29]. In contrast, it is better known that the α IIb β 3 integrin plays a central role in recognizing C. albicans [30]. In addition, Dectin-1 and CD206, identified on platelets in this study, could have a relevant role in binding C. albicans based on the background of these receptors [31,32].…”

Section: Discussionmentioning

confidence: 63%

LL-37 Triggers Antimicrobial Activity in Human Platelets

Sánchez-Peña

Romero-Tlalolini

Torres-Aguilar

et al. 2023

IJMS

View full text Add to dashboard Cite

Platelets play a crucial role in hemostasis and the immune response, mainly by recognizing signals associated with vascular damage. However, it has recently been discovered that the antimicrobial peptide LL-37 activates platelets in functions related to thrombus formation and inflammation. Therefore, this work aims to evaluate the effect of LL-37 on the activation of antimicrobial functions of human platelets. Our results show that platelets treated with LL-37 increase the surface expression of receptors (Toll-like receptors (TLRs) 2 and -4, CD32, CD206, Dectin-1, CD35, LOX-1, CD41, CD62P, and αIIbβ3 integrins) for the recognition of microorganisms, and molecules related to antigen presentation to T lymphocytes (CD80, CD86, and HLA-ABC) secrete the antimicrobial molecules: bactericidal/permeability-increasing protein (BPI), azurocidin, human neutrophil peptide (HNP) -1, and myeloperoxidase. They also translate azurocidin, and have enhanced binding to Escherichia coli, Staphylococcus aureus, and Candida albicans. Furthermore, the supernatant of LL-37-treated platelets can inhibit E. coli growth, or platelets can employ their LL-37 to inhibit microbial growth. In conclusion, these findings demonstrate that LL-37 participates in the antimicrobial function of human platelets.

show abstract

Section: Discussionmentioning

confidence: 63%

LL-37 Triggers Antimicrobial Activity in Human Platelets

Sánchez-Peña

Romero-Tlalolini

Torres-Aguilar

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In another study, plasma L-arginine levels were shown to correlate inversely with the severity of COVID-19 [23]. This study also showed that the expression of the activated GP IIb/IIIa complex, known to be involved in platelet activation [23,24], is higher in patients with severe COVID-19 compared to healthy patients and inversely correlated with the plasma concentration of L-arginine [25].…”

Section: Introductionmentioning

confidence: 59%

“…Qualitative studies to date have examined wider patient experience. They revealed several common themes, including symptom variability, physical and intellectual fatigue, patients' burden of accessing care and fear of a permanent reduction in physical and cognitive abilities [16][17][18][19][20][21][22][23][24][25][26][27]. Cognitive complaints and persistent fatigue have been reported in the literature among the most debilitating symptoms for patients diagnosed with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…The ten items of the questionnaire reflect both mental and physical fatigue, with a 5-point scale response, so the total FAS score ranges from 10 to 50. A respondent has no fatigue (normal) if FAS score is equal to or less than 21; otherwise, the respondent has substantial fatigue (score [22][23][24][25][26][27][28][29][30][31][32][33][34] or extreme fatigue (score ≥ 35) [34]. The Romanian version of FAS was used in this study [40,43].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Arginine-Based Supplements on Fatigue Levels following COVID-19 Infection: A Prospective Study in Romania

et al. 2023

View full text Add to dashboard Cite

The purpose of this study was to examine the effects of two arginine-based supplements on the fatigue level of patients following the COVID-19 infection. This is a prospective study of the SARS-CoV-2-infected patients divided into two groups (according to family physicians’ prescriptions, Group 1 of patients were treated with Astenor Energy® containing arginine aspartate, B6 vitamin, biotin and magnesium, and Group 2 of patients were treated with Astenor Forte® containing L-arginine and malic acid). The patients visited their family physicians from October 2021 to January 2022, complaining of physical and/or mental fatigue following the COVID-19 infection. We recorded 505 patients (146 patients in Group 1 and 359 patients in Group 2) and analyzed the fatigue level using the Fatigue Assessment Scale (FAS) through its total (FAS-T), mental (FAS-M) and physical (FAS-P) scores, at baseline and after three months of treatment. There was no difference between the two groups in terms of age (p = 0.265), but more men were included in Group 1 than in Group 2 (p = 0.001). The patients from Group 2 were significantly more likely to be treated at home than those included in Group 1 (89.7% vs. 65.1%, p < 0.0001) because of the lower severity of the COVID-19 infection (asymptomatic or mild: 82.5% vs. 48.7%, p < 0.0001). After 3 months of treatment, patients indicated no fatigue in the higher percentage compared to than at the baseline (68.7% vs. 27.7%), and the fatigue level significantly decreased both in Group 1 (median baseline 33.0 vs. follow-up 17.00, p < 0.0001) and Group 2 (median baseline 25.0 vs. follow-up 17.00, p < 0.0001). These findings suggest that supplements with L-arginine may be proposed as a remedy to restore physical and mental performance affected by the fatigue burden in people with COVID-19 or following the COVID-19 infection.

show abstract

“…To analyze the transcription of the efflux system genes MDR1, CDR1 , and CDR2, the PCR was performed using PCR amplifier "BioRad CFX96" (BioRad, Singapore) using Extra Mix for reverse transcription and quantitative real-time PCR in a one-step method (BioLabMix, Novosibirsk, Russia) with SYBR Blue under conditions recommended by the manufacturer. The oligonucleotides used for the qRT-PCR are shown in Table 1 [ 66 , 67 , 68 ]. A total RNA was extracted from planktonic C. albicans 688 cells subjected to 48-h treatment with either fluconazole or F131 .…”

Section: Methodsmentioning

confidence: 99%

Antimicrobial and Biofilm-Preventing Activity of l-Borneol Possessing 2(5H)-Furanone Derivative F131 against S. aureus—C. albicans Mixed Cultures

et al. 2022

View full text Add to dashboard Cite

Candida albicans and Staphylococcus aureus are human pathogens that are able to form mixed biofilms on the surface of mucous membranes, implants and catheters. In biofilms, these pathogens have increased resistance to antimicrobials, leading to extreme difficulties in the treatment of mixed infections. The growing frequency of mixed infections caused by S. aureus and C. albicans requires either the development of new antimicrobials or the proposal of alternative approaches to increase the efficiency of conventional ones. Here, we show the antimicrobial, biofilm-preventing and biofilm-eradicating activity of 2(5H)-furanone derivative F131, containing an l-borneol fragment against S. aureus–C. albicans mixed biofilms. Furanone F131 is also capable of inhibiting the formation of monospecies and mixed biofilms by S. aureus and C. albicans. The minimal biofilm-prevention concentration (MBPC) of this compound was 8–16 μg/mL for S. aureus and C. albicans mono- and two-species biofilms. While the compound demonstrates slightly lower activity compared to conventional antimicrobials (gentamicin, amikacin, fluconazole, terbinafine and benzalkonium chloride), F131 also increases the antimicrobial activity of fluconazole–gentamicin and benzalkonium chloride against mixed biofilms of S. aureus–C. albicans, thus reducing MBPC of fluconazole–gentamicin by 4–16 times and benzalkonium chloride twofold. F131 does not affect the transcription of the MDR1, CDR1 and CDR2 genes, thus suggesting a low risk of micromycete resistance to this compound. Altogether, combined use of antibiotics with a F131 could be a promising option to reduce the concentration of fluconazole used in antiseptic compositions and reduce the toxic effect of benzalkonium chloride and gentamicin. This makes them an attractive starting point for the development of alternative antimicrobials for the treatment of skin infections caused by S. aureus–C. albicans mixed biofilms.

show abstract

GP IIb/IIIa-Mediated Platelet Activation and Its Modulation of the Immune Response of Monocytes Against Candida albicans

Cited by 3 publications

References 47 publications

LL-37 Triggers Antimicrobial Activity in Human Platelets

LL-37 Triggers Antimicrobial Activity in Human Platelets

The Effects of Arginine-Based Supplements on Fatigue Levels following COVID-19 Infection: A Prospective Study in Romania

Antimicrobial and Biofilm-Preventing Activity of l-Borneol Possessing 2(5H)-Furanone Derivative F131 against S. aureus—C. albicans Mixed Cultures

Contact Info

Product

Resources

About